Saleem Husain, MD | |
1314 Park Ave, Suite 9, Plainfield, NJ 07060-3253 | |
(908) 222-8970 | |
(908) 222-8762 |
Full Name | Saleem Husain |
---|---|
Gender | Male |
Speciality | Cardiovascular Disease (cardiology) |
Experience | 34 Years |
Location | 1314 Park Ave, Plainfield, New Jersey |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1134197346 | NPI | - | NPPES |
7019301 | Medicaid | NJ |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RC0000X | Internal Medicine - Cardiovascular Disease | MA058027 (New Jersey) | Primary |
207R00000X | Internal Medicine | MA058027 (New Jersey) | Secondary |
Facility Name | Location | Facility Type |
---|---|---|
Jfk Medical Center | Edison, NJ | Hospital |
Robert Wood Johnson University Hospital - Somerset | Somerville, NJ | Hospital |
Robert Wood Johnson University Hospital | New brunswick, NJ | Hospital |
Overlook Medical Center | Summit, NJ | Hospital |
Entity Name | Hackensack Meridian Health Medical Group - Specialty Care Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1215989249 PECOS PAC ID: 9133032519 Enrollment ID: O20031111000524 |
News Archive
Valeant Pharmaceuticals International, Inc. announced today that its subsidiary, Valeant International SRL (VIB), has signed an agreement to acquire rights to both Elidel and Xerese from Meda, an international specialty pharmaceutical company for the U.S., Canada and Mexico.
This week, a new vaccine "VPM1002" has entered the clinical phase I trial in Neuss, Germany, where it is being tested for safety on voluntary subjects. VPM1002 is based on a vaccine that has been in use since 1921, and has been genetically engineered to prevent infection with tuberculosis bacteria much more effectively than its predecessor.
Sanofi-aventis announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra (insulin glulisine [rDNA origin] injection) before meals improved glycemic control and reduced hospital complications, compared to "sliding scale" insulin in general surgery patients with type 2 diabetes.
Public health officials may soon be able to flush out more accurate estimates on illegal drug use in communities across the country thanks to screening test described at the 234 th national meeting of the American Chemical Society, the world's largest scientific society.
› Verified 3 days ago
Entity Name | Community Hospital Group Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1225251754 PECOS PAC ID: 3971415209 Enrollment ID: O20031120000589 |
News Archive
Valeant Pharmaceuticals International, Inc. announced today that its subsidiary, Valeant International SRL (VIB), has signed an agreement to acquire rights to both Elidel and Xerese from Meda, an international specialty pharmaceutical company for the U.S., Canada and Mexico.
This week, a new vaccine "VPM1002" has entered the clinical phase I trial in Neuss, Germany, where it is being tested for safety on voluntary subjects. VPM1002 is based on a vaccine that has been in use since 1921, and has been genetically engineered to prevent infection with tuberculosis bacteria much more effectively than its predecessor.
Sanofi-aventis announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra (insulin glulisine [rDNA origin] injection) before meals improved glycemic control and reduced hospital complications, compared to "sliding scale" insulin in general surgery patients with type 2 diabetes.
Public health officials may soon be able to flush out more accurate estimates on illegal drug use in communities across the country thanks to screening test described at the 234 th national meeting of the American Chemical Society, the world's largest scientific society.
› Verified 3 days ago
Entity Name | Cardiovascular Health Consultants, P.a. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1437291739 PECOS PAC ID: 8325934706 Enrollment ID: O20040224000028 |
News Archive
Valeant Pharmaceuticals International, Inc. announced today that its subsidiary, Valeant International SRL (VIB), has signed an agreement to acquire rights to both Elidel and Xerese from Meda, an international specialty pharmaceutical company for the U.S., Canada and Mexico.
This week, a new vaccine "VPM1002" has entered the clinical phase I trial in Neuss, Germany, where it is being tested for safety on voluntary subjects. VPM1002 is based on a vaccine that has been in use since 1921, and has been genetically engineered to prevent infection with tuberculosis bacteria much more effectively than its predecessor.
Sanofi-aventis announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra (insulin glulisine [rDNA origin] injection) before meals improved glycemic control and reduced hospital complications, compared to "sliding scale" insulin in general surgery patients with type 2 diabetes.
Public health officials may soon be able to flush out more accurate estimates on illegal drug use in communities across the country thanks to screening test described at the 234 th national meeting of the American Chemical Society, the world's largest scientific society.
› Verified 3 days ago
Entity Name | Saleem Husain Md Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1518982388 PECOS PAC ID: 0345208096 Enrollment ID: O20050110000091 |
News Archive
Valeant Pharmaceuticals International, Inc. announced today that its subsidiary, Valeant International SRL (VIB), has signed an agreement to acquire rights to both Elidel and Xerese from Meda, an international specialty pharmaceutical company for the U.S., Canada and Mexico.
This week, a new vaccine "VPM1002" has entered the clinical phase I trial in Neuss, Germany, where it is being tested for safety on voluntary subjects. VPM1002 is based on a vaccine that has been in use since 1921, and has been genetically engineered to prevent infection with tuberculosis bacteria much more effectively than its predecessor.
Sanofi-aventis announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra (insulin glulisine [rDNA origin] injection) before meals improved glycemic control and reduced hospital complications, compared to "sliding scale" insulin in general surgery patients with type 2 diabetes.
Public health officials may soon be able to flush out more accurate estimates on illegal drug use in communities across the country thanks to screening test described at the 234 th national meeting of the American Chemical Society, the world's largest scientific society.
› Verified 3 days ago
Entity Name | Hmh Hospitals Corporation |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1356016661 PECOS PAC ID: 9032181847 Enrollment ID: O20220304001385 |
News Archive
Valeant Pharmaceuticals International, Inc. announced today that its subsidiary, Valeant International SRL (VIB), has signed an agreement to acquire rights to both Elidel and Xerese from Meda, an international specialty pharmaceutical company for the U.S., Canada and Mexico.
This week, a new vaccine "VPM1002" has entered the clinical phase I trial in Neuss, Germany, where it is being tested for safety on voluntary subjects. VPM1002 is based on a vaccine that has been in use since 1921, and has been genetically engineered to prevent infection with tuberculosis bacteria much more effectively than its predecessor.
Sanofi-aventis announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra (insulin glulisine [rDNA origin] injection) before meals improved glycemic control and reduced hospital complications, compared to "sliding scale" insulin in general surgery patients with type 2 diabetes.
Public health officials may soon be able to flush out more accurate estimates on illegal drug use in communities across the country thanks to screening test described at the 234 th national meeting of the American Chemical Society, the world's largest scientific society.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Saleem Husain, MD 1314 Park Ave, Suite 9, Plainfield, NJ 07060-3253 Ph: (908) 222-8970 | Saleem Husain, MD 1314 Park Ave, Suite 9, Plainfield, NJ 07060-3253 Ph: (908) 222-8970 |
News Archive
Valeant Pharmaceuticals International, Inc. announced today that its subsidiary, Valeant International SRL (VIB), has signed an agreement to acquire rights to both Elidel and Xerese from Meda, an international specialty pharmaceutical company for the U.S., Canada and Mexico.
This week, a new vaccine "VPM1002" has entered the clinical phase I trial in Neuss, Germany, where it is being tested for safety on voluntary subjects. VPM1002 is based on a vaccine that has been in use since 1921, and has been genetically engineered to prevent infection with tuberculosis bacteria much more effectively than its predecessor.
Sanofi-aventis announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra (insulin glulisine [rDNA origin] injection) before meals improved glycemic control and reduced hospital complications, compared to "sliding scale" insulin in general surgery patients with type 2 diabetes.
Public health officials may soon be able to flush out more accurate estimates on illegal drug use in communities across the country thanks to screening test described at the 234 th national meeting of the American Chemical Society, the world's largest scientific society.
› Verified 3 days ago
Eva Besserman, D.O. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: Muhlenberg Regional Medical Center, Park Ave. & Randolph Rd., Plainfield, NJ 07061 Phone: 908-668-2228 Fax: 908-226-4543 | |
Dr. Harsha Tripathi, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1700 Myrtle Ave, Plainfield, NJ 07063 Phone: 908-753-6401 Fax: 908-226-6743 | |
Dr. David Alan Goldenberg, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1165 Park Ave, Plainfield, NJ 07060 Phone: 908-754-2992 | |
Dr. Susan Walsh, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1700 Myrtle Ave, Plainfield, NJ 07063 Phone: 908-753-6401 | |
Dr. Padmaja Isukapalli, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1024 Park Ave, Suite 6 A, Plainfield, NJ 07060 Phone: 908-222-8400 Fax: 908-222-8402 | |
Dr. Janet C Lin, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: Muhlenberg Regional Medical Center, Park Ave And Randolph Rd, Plainfield, NJ 07061 Phone: 908-668-2985 Fax: 908-226-4543 |